Immunotherapy News and Research RSS Feed - Immunotherapy News and Research

Immunotherapy is the concept of using the immune system to treat disease, for example, developing a vaccine against cancer. Immunotherapy may also refer to the therapy of diseases caused by the immune system, allergies for example.
Scientists identify white blood cells that tumors use to suppress disease-fighting immune system

Scientists identify white blood cells that tumors use to suppress disease-fighting immune system

A study led by St. Jude Children's Research Hospital scientists has identified the population of white blood cells that tumors use to enhance growth and suppress the disease-fighting immune system. [More]
Inovio begins hTERT DNA immunotherapy trial in adults with breast, lung and pancreatic cancer

Inovio begins hTERT DNA immunotherapy trial in adults with breast, lung and pancreatic cancer

Inovio Pharmaceuticals, Inc. announced it has initiated a phase I trial of its hTERT DNA immunotherapy (INO-1400) alone or in combination with Inovio's IL-12 immune activator (INO-9012) in adults with breast, lung, or pancreatic cancer at high risk of relapse after surgery and other cancer treatments. [More]

EC grants orphan drug designation to TxCell's Col-Treg for treatment of autoimmune uveitis

TxCell SA, a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that the European Commission (EC) has granted orphan drug designation to TxCell's investigational medicinal product Col-Treg, a personalized T cell immunotherapy using collagen-II specific regulatory T-cells, for the treatment of autoimmune uveitis. [More]
Scientists produce novel class of molecules that could help combat cancer, other diseases

Scientists produce novel class of molecules that could help combat cancer, other diseases

Promising treatments known as biologics are on the market and under development for many serious illnesses such as cancer, but some of them come with high risks, even lethal ones. Now scientists have produced a novel class of molecules that could be as effective but without the dangerous side effects. [More]
PD-L1 expression tied to favourable prognosis in SCLC

PD-L1 expression tied to favourable prognosis in SCLC

Programmed death-ligand 1 is expressed by around 70% of small-cell lung cancers and is associated with favourable patient outcomes, Japanese researchers report. [More]
Kiadis Pharma reports positive interim data from ATIR Phase II clinical study

Kiadis Pharma reports positive interim data from ATIR Phase II clinical study

Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing T-cell immunotherapy treatments for blood cancers, today announces positive interim data from the ongoing Phase II clinical study with its lead product ATIR. [More]
Study: Injectable 3D vaccines could help prevent cancer, infectious disease

Study: Injectable 3D vaccines could help prevent cancer, infectious disease

One of the reasons cancer is so deadly is that it can evade attack from the body's immune system, which allows tumors to flourish and spread. Scientists can try to induce the immune system, known as immunotherapy, to go into attack mode to fight cancer and to build long lasting immune resistance to cancer cells. [More]
Amgen announces new data from BLINCYTO Phase 2 study for treatment of patients with ALL

Amgen announces new data from BLINCYTO Phase 2 study for treatment of patients with ALL

Amgen today announced that new data from a pivotal Phase 2 study evaluating BLINCYTO (blinatumomab) for the treatment of adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (ALL) was presented at the 56th American Society of Hematology Annual Meeting and Exposition. [More]
Studies presented at ASH meeting compare new, standard-of-care treatments for blood clots

Studies presented at ASH meeting compare new, standard-of-care treatments for blood clots

Studies presented at the 56th American Society of Hematology Annual Meeting and Exposition compare new and standard-of-care treatments for blood clots and further illuminate clot risks in vulnerable populations, such as cancer patients. [More]
Cornerstone Pharmaceuticals initiates CPI-613 Phase I trial in patients with B-cell NHL

Cornerstone Pharmaceuticals initiates CPI-613 Phase I trial in patients with B-cell NHL

Cornerstone Pharmaceuticals, Inc., a clinical stage company and leader in the growing field of cancer metabolism-based therapeutics, today announced the initiation of a Phase I clinical trial assessing the safety and efficacy of escalating doses of CPI-613, in combination with bendamustine and rituximab, in patients with relapsed or refractory B-cell Non-Hodgkin lymphoma (NHL). [More]
iTeos Therapeutics, Pfizer form strategic collaboration for cancer immunotherapeutics

iTeos Therapeutics, Pfizer form strategic collaboration for cancer immunotherapeutics

iTeos Therapeutics SA announced today a strategic collaboration with Pfizer Inc. pursuant to which iTeos will license to Pfizer rights to iTeos' pre-clinical compounds targeting Indoleamine 2,3-dioxygenase (IDO1) and Tryptophan 2,3-dioxygenase (TDO2). Pfizer will be responsible for the development and commercialization of IDO1 and TDO2 drug candidates. [More]
Novel targeted therapies and treatment combinations for leukemia

Novel targeted therapies and treatment combinations for leukemia

Recognizing that leukemia cannot be conquered with a "one-size-fits-all" approach, researchers are pursuing novel targeted therapies and combinations of existing treatment regimens with new agents for patient populations with historically poor prognoses, according to data presented today during the 56th American Society of Hematology Annual Meeting and Exposition. [More]
Breakthrough therapy shows promise in resistant forms of Hodgkin lymphoma

Breakthrough therapy shows promise in resistant forms of Hodgkin lymphoma

A therapy that liberates the immune system to attack cancer cells drove Hodgkin lymphoma (HL) into complete or partial remission in fully 87 percent of patients with resistant forms of the disease who participated in an early-phase clinical trial, investigators at Dana-Farber Cancer Institute and partnering institutions report in a study published today in the New England Journal of Medicine and simultaneously presented at the annual meeting of the American Society of Hematology in San Francisco. [More]
Emerging strategies to boost healthy RBCs may reduce burden of anemia linked to blood disorders

Emerging strategies to boost healthy RBCs may reduce burden of anemia linked to blood disorders

Emerging treatment approaches may reduce the burden of anemia associated with blood disorders by enhancing production of healthy red blood cells, according to data presented today at the 56th American Society of Hematology Annual Meeting and Exposition. [More]
New treatment combinations improve outcomes for vulnerable patient with hard-to-treat disease

New treatment combinations improve outcomes for vulnerable patient with hard-to-treat disease

New treatment combinations and targeted therapies for lymphoma and multiple myeloma are improving outcomes for vulnerable patient populations with hard-to-treat disease, according to studies presented today at the 56th American Society of Hematology Annual Meeting and Exposition. [More]
Novel treatments show promising results in patients with different hematologic disorders

Novel treatments show promising results in patients with different hematologic disorders

In recent years, a number of scientific breakthroughs have led to the development of drugs that unleash the power of the immune system to recognize and attack cancer. Studies presented today at the 56th Annual Meeting of the American Society of Hematology highlight the enormous potential these novel treatments have for patients with a variety of hematologic disorders. [More]
Study: Key protein may help prevent tumor growth, promote wound healing

Study: Key protein may help prevent tumor growth, promote wound healing

A key protein may represent a new way to use the immune system to speed healing and counter inflammatory, infectious and autoimmune diseases, according to study led by researchers at the Icahn School of Medicine at Mount Sinai and published in the December issue of Cell Reports. [More]
Innovative cell therapy shows highly promising results in pediatric patients with ALL

Innovative cell therapy shows highly promising results in pediatric patients with ALL

An innovative cell therapy against a highly aggressive form of acute lymphoblastic leukemia (ALL) continues to show highly promising results in children treated in a pilot study. Ninety-two percent of the 39 children receiving bioengineered T cells had no evidence of cancer at one month after treatment, with this complete response persisting in some cases for more than two years. [More]
Novel treatments show safe responses in patients with relapsed, treatment-resistant blood cancers

Novel treatments show safe responses in patients with relapsed, treatment-resistant blood cancers

Novel treatments that harness the body's own immune cells to attack cancer cells demonstrate safe and durable responses in patients with relapsed and treatment-resistant blood cancers, according to data presented today at the 56th American Society of Hematology Annual Meeting and Exposition. [More]
Oncologists examine efficacy of rose bengal against cancer

Oncologists examine efficacy of rose bengal against cancer

Rose Bengal has been around for decades starting as a way to dye wool. Originally used in medicine as a stain for ophthalmologists, it has a solid safety record going back to the 1930s. Recently, oncologists have examined its efficacy against cancer, specifically melanoma. [More]